Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain.
Changes in glycinergic neurotransmission in the spinal cord dorsal horn are critically involved in the development of pathological pain. Since the concentration of glycine in the synaptic cleft is controlled by specialized proteins, the glycine transporters GlyT1 and GlyT2, manipulation of this system might have significant effects on nociception. In the present study, we investigated the effects of the spinally applied glycine transporter inhibitors ALX 5407 (GlyT1) and ALX 1393 (GlyT2) on nociceptive behavior in the chronic constriction injury model of neuropathic pain in male Wistar rats. After implementation of neuropathy, the animals were injected with three dosages of ALX 5407 and ALX 1393 (10, 50 and 100 microg) via an intrathecal catheter (n = 8 each). Subsequently, nociceptive behavior was evaluated regarding thermal hyperalgesia (Hargreaves method) and mechanical sensitization (von Frey filaments) over 240 min after application. Inhibition of GlyT1 by ALX 5407 had differential dose-dependent effects. While the highest and the lowest concentrations were antinociceptive, the medium dose evoked pronociceptive effects. The GlyT2 inhibitor ALX 1393 was only effective in the highest concentration at which it exerted significant antinociception. However, in the same dose, ALX 1393 caused remarkable side effects such as respiratory depression and motor deficits in three animals. Our findings indicate that inhibition of glycine transporters is capable of evoking significant effects on nociceptive behavior in neuropathic pain. Whether glycine transporter inhibitors have the capability to gain clinical relevance as analgesic compounds on the long run has to be elucidated in further investigations.
Hermanns
Henning
H
Department of Anesthesiology, University Hospital Düsseldorf, Düsseldorf, Germany. Henning.Hermanns@uni-duesseldorf.de
Muth-Selbach
Uta
U
Williams
Ruth
R
Krug
Sabrina
S
Lipfert
Peter
P
Werdehausen
Robert
R
Braun
Sebastian
S
Bauer
Inge
I
D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007839:Functional Laterality / Q000187:drug effects; D050487:Glycine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors*; D007278:Injections, Spinal / Q000379:methods; D008297:Male; D010147:Pain Measurement; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D012521:Sarcosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012585:Sciatica / Q000188:drug therapy* / Q000503:physiopathology; D012694:Serine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
C510369:(R)-(N-(3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl))sarcosine; C539864:ALX 1393; D050487:Glycine Plasma Membrane Transport Proteins; D012694:Serine; D012521:Sarcosine